Tumor Biology

, Volume 37, Issue 7, pp 9649–9656 | Cite as

Expression of the anti-inflammatory suppressor of cytokine signaling 3 (SOCS3) in human clear cell renal cell carcinoma

  • Anja Urbschat
  • Svenja Stumpf
  • Jörg Hänze
  • Patrick Paulus
  • Thorsten J. Maier
  • Christine Weipert
  • Rainer Hofmann
  • Axel Hegele
Original Article


The oncogenic transcription factor signal transducer and activator of transcription 3 (STAT3) is a cytokine-activated transcription factor controlling inflammation, cell proliferation, survival, and differentiation in normal tissue as well as in tumor growth. One of its most important negative regulators is the suppressor of cytokine signaling 3 (SOCS3). Here, we analyzed SOCS3 and other tumor-associated local immune regulators in human clear cell renal cell carcinoma (ccRCC). Analyses were performed in tumor and adjacent tumor-free healthy renal tissue from 35 patients with ccRCC. For functional analysis, ccRCC Caki-1 cell lines were stimulated with IL-6 and IFNγ in cell culture assays. We observed significantly lower SOCS3 messenger RNA (mRNA) levels in tumor tissue compared to healthy tissue. SOCS3 mRNA strongly correlated within tumor and healthy tissue. Interestingly vice versa, SOCS3 protein levels were significantly higher in tumor tissue than in healthy tissue. IL-22 and IL-22R1 mRNA displayed no differences in tumor and healthy tissue. Stimulation of Caki-1 cells with IFNγ resulted in markedly increased SOCS3 mRNA levels. We conclude that SOCS3 along with STAT3 participates in regulatory mechanisms in ccRCC, which certainly features only one of multiple factors involved but nevertheless merits further attention.


Clear cell renal cell carcinoma SOCS3 STAT3 JAK2 



We especially thank Ecatarina Oplesch for her technical support.

Compliance with ethical standards

Conflicts of interest


Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


This study was financially supported by a junior researchers grant to A.U. (Fokus Programm, Förderlinie A from the Goethe-University Frankfurt) and by the German Research Foundation (DFG projects MA-5825/1-1) to T.J.M. The founders of the study had no role in design, interpretation of the data, nor in the decision to publish.


  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int J Cancer. 2015;136:E359–386.CrossRefPubMedGoogle Scholar
  2. 2.
    Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–71.CrossRefPubMedGoogle Scholar
  5. 5.
    Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, et al. Japan Immunotherapy S-SGfKC: Stat3 polymorphism can predict the response to interferon-alpha therapy in patients with metastatic renal cell carcinoma. Eur Urol. 2013;63:745–52.CrossRefPubMedGoogle Scholar
  6. 6.
    Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, et al. Stat3 inhibitor wp1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer. 2010;102:1592–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol. 2002;168:762–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Darnell Jr JE. Stats and gene regulation. Science. 1997;277:1630–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Yoshimura A, Naka T, Kubo M. Socs proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7:454–65.CrossRefPubMedGoogle Scholar
  10. 10.
    Yamamoto K, Yamaguchi M, Miyasaka N, Miura O. Socs-3 inhibits il-12-induced stat4 activation by binding through its sh2 domain to the stat4 docking site in the il-12 receptor beta2 subunit. Biochem Biophys Res Commun. 2003;310:1188–93.CrossRefPubMedGoogle Scholar
  11. 11.
    Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, et al. Cis3/socs3/ssi3 plays a negative regulatory role in stat3 activation and intestinal inflammation. J Exp Med. 2001;193:471–81.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, et al. Induction of the cytokine signal regulator socs3/cis3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest. 2001;108:1781–8.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Gomez-Guerrero C, Lopez-Franco O, Sanjuan G, Hernandez-Vargas P, Suzuki Y, Ortiz-Munoz G, et al. Suppressors of cytokine signaling regulate fc receptor signaling and cell activation during immune renal injury. J Immunol. 2004;172:6969–77.CrossRefPubMedGoogle Scholar
  14. 14.
    He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. Socs-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A. 2003;100:14133–8.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Li G, Xu J, Wang Z, Yuan Y, Li Y, Cai S, He Y: Low expression of socs-1 and socs-3 is a poor prognostic indicator for gastric cancer patients. J Cancer Res Clin Oncol 2014.Google Scholar
  16. 16.
    Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y, et al. Deletion of the socs3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology. 2006;131:179–93.CrossRefPubMedGoogle Scholar
  17. 17.
    Stofas A, Levidou G, Piperi C, Adamopoulos C, Dalagiorgou G, Bamias A, et al. The role of cxc-chemokine receptor cxcr2 and suppressor of cytokine signaling-3 (socs-3) in renal cell carcinoma. BMC Cancer. 2014;14:149.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Erdogan F, Demirel A, Polat O. Prognostic significance of morphologic parameters in renal cell carcinoma. Int J Clin Pract. 2004;58:333–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T. Prognostic impact of carbonic anhydrase ix expression in human renal cell carcinoma. BJU Int. 2007;100:556–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Walther MM, Johnson B, Culley D, Shah R, Weber J, Venzon D, et al. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol. 1998;159:718–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917–21.CrossRefPubMedGoogle Scholar
  22. 22.
    Hoegl S, Bachmann M, Scheiermann P, Goren I, Hofstetter C, Pfeilschifter J, et al. Protective properties of inhaled il-22 in a model of ventilator-induced lung injury. Am J Respir Cell Mol Biol. 2011;44:369–76.CrossRefPubMedGoogle Scholar
  23. 23.
    Horiguchi A, Oya M, Marumo K, Murai M. Stat3, but not erks, mediates the il-6-induced proliferation of renal cancer cells, achn and 769p. Kidney Int. 2002;61:926–38.CrossRefPubMedGoogle Scholar
  24. 24.
    Yu H, Pardoll D, Jove R. Stats in cancer inflammation and immunity: a leading role for stat3. Nat Rev Cancer. 2009;9:798–809.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Si H, Banga RS, Kapitsinou P, Ramaiah M, Lawrence J, Kambhampati G, et al. Human and murine kidneys show gender- and species-specific gene expression differences in response to injury. PLoS ONE. 2009;4:e4802.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Neuwirt H, Eder IE, Puhr M, Rudnicki M. Socs-3 is downregulated in progressive ckd patients and regulates proliferation in human renal proximal tubule cells in a stat1/3 independent manner. Lab Investig. 2013;93:123–34.CrossRefPubMedGoogle Scholar
  27. 27.
    Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract. 1986;181:125–43.CrossRefPubMedGoogle Scholar
  28. 28.
    Guo C, Yang G, Khun K, Kong X, Levy D, Lee P, et al. Activation of stat3 in renal tumors. Am J Transl Res. 2009;1:283–90.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol. 2000;18:143–64.CrossRefPubMedGoogle Scholar
  30. 30.
    Wolk K, Sabat R. Interleukin-22: a novel t- and nk-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. 2006;17:367–80.CrossRefPubMedGoogle Scholar
  31. 31.
    Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. Il-22 increases the innate immunity of tissues. Immunity. 2004;21:241–54.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Anja Urbschat
    • 1
  • Svenja Stumpf
    • 1
  • Jörg Hänze
    • 1
  • Patrick Paulus
    • 2
  • Thorsten J. Maier
    • 3
  • Christine Weipert
    • 4
  • Rainer Hofmann
    • 1
  • Axel Hegele
    • 1
  1. 1.Department of Urology and Pediatric UrologyUniversity Hospital of the Philipps-University MarburgMarburgGermany
  2. 2.Department of Anesthesiology and Operative Intensive Care MedicineKepler University Hospital LinzLinzAustria
  3. 3.Department of BiomedicineAarhus UniversityAarhusDenmark
  4. 4.Clinic of Urology and Andrology, Landeskrankenhaus Hall in TirolHallAustria

Personalised recommendations